G1 Therapeutics Inc (GTHX)
3.31
0.00 (0.00%)
USD |
NASDAQ |
May 31, 16:00
3.305
0.00 (0.00%)
After-Hours: 20:00
G1 Therapeutics Research and Development Expense (Quarterly): 7.318M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 7.318M |
December 31, 2023 | 7.38M |
September 30, 2023 | 8.811M |
June 30, 2023 | 12.04M |
March 31, 2023 | 15.48M |
December 31, 2022 | 16.59M |
September 30, 2022 | 19.58M |
June 30, 2022 | 20.84M |
March 31, 2022 | 26.30M |
December 31, 2021 | 19.79M |
September 30, 2021 | 21.14M |
June 30, 2021 | 18.75M |
March 31, 2021 | 16.54M |
December 31, 2020 | 16.37M |
September 30, 2020 | 17.93M |
June 30, 2020 | 18.53M |
March 31, 2020 | 20.43M |
Date | Value |
---|---|
December 31, 2019 | 24.49M |
September 30, 2019 | 22.94M |
June 30, 2019 | 23.49M |
March 31, 2019 | 18.08M |
December 31, 2018 | 19.08M |
September 30, 2018 | 15.87M |
June 30, 2018 | 18.38M |
March 31, 2018 | 17.35M |
December 31, 2017 | 15.08M |
September 30, 2017 | 14.05M |
June 30, 2017 | 13.67M |
March 31, 2017 | 11.08M |
December 31, 2016 | 9.141M |
September 30, 2016 | 5.695M |
June 30, 2016 | 6.454M |
March 31, 2016 | 3.872M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.318M
Minimum
Mar 2024
26.30M
Maximum
Mar 2022
17.74M
Average
18.64M
Median
Research and Development Expense (Quarterly) Benchmarks
NovaBay Pharmaceuticals Inc | 0.019M |
Palatin Technologies Inc | 7.160M |
iBio Inc | 0.904M |
Theriva Biologics Inc | 3.459M |
Oragenics Inc | 0.6634M |